Genenta Science (NASDAQ:GNTA) Trading Down 1.3% – What’s Next?

Shares of Genenta Science S.p.A. (NASDAQ:GNTA) dropped 1.3% during mid-day trading on Friday . The company traded as low as $3.51 and last traded at $3.76. Approximately 22,483 shares were traded during trading, an increase of 43% from the average daily volume of 15,753 shares. The stock had previously closed at $3.81.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Genenta Science in a report on Wednesday, October 2nd.

Genenta Science Stock Down 1.3 %

The business’s 50 day moving average price is $4.88 and its two-hundred day moving average price is $4.56.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. bought a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science as of its most recent SEC filing. Hedge funds and other institutional investors own 15.13% of the company’s stock.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.